Breaking Finance News

Shire PLC (LON:SHP) target price lowered to 6,000.00GBX, reported today by Berenberg

Boasting a price of 4,394.50GBX, Shire PLC (LON:SHP) traded 0.08% higher on the day. With the last stock price close up -9.68% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Shire PLC has recorded a 50-day average of 3,859.92GBX and a two hundred day average of 4,260.51GBX. Volume of trade was down over the average, with 1,190,434 shares of SHP changing hands under the typical 2,708,590

Shire PLC (LON:SHP) had its target bumped down to 6,000.00GBX by Berenberg in an issued report announced 6/8/2017. The bumped down target suggests a potential upside of 0.37% from the company's most recent stock price close.

On 06/01/2017, Liberum Capital released a statement for Shire PLC (LON:SHP) bumped down the target price from 5,500.00GBX to 4,900.00GBX that suggested an upside of 0.06%.

Recent Performance Chart


Shire PLC has PE ratio of 51.65 with a one year low of 3,603.50GBX and a one year high of 5,210.00GBX and has a market capitalization of 0 GBX.

A total of 18 brokerages have issued a ratings update on Shire PLC. Six brokerages rating the company a strong buy, sixteen brokerages rating the company a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a consensus target price of 73.73GBX.

General Information About Shire PLC (LON:SHP)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.